Ascendis Pharma A (ASND) Curent Deferred Tax Liability (2017 - 2018)
Ascendis Pharma A's (ASND) quarterly Curent Deferred Tax Liability came in at -$6391.8 in Q4 2018, down 133.99% year-on-year from $18804.0 in Q4 2017, and down 133.99% quarter-over-quarter from -$2731.6 in Q4 2017.
Ascendis Pharma A (ASND) Curent Deferred Tax Liability (2017 - 2018) Analysis & Trends
Ascendis Pharma A has disclosed Curent Deferred Tax Liability across 2 years of filings, most recently posting -$6391.8 for Q4 2018.
- Curent Deferred Tax Liability for Q4 2018 came in at -$6391.8, down 133.99% year-over-year; the trailing twelve-month figure through Dec 2018 was -$6391.8 (down 133.99% YoY), and the FY2018 annual result was -$6391.8, down 133.99% from the prior year.
- Curent Deferred Tax Liability came in at -$6391.8 for Q4 2018 at Ascendis Pharma A, down from -$2731.6 in the prior quarter.
- In the past five years, Curent Deferred Tax Liability ranged from a high of -$2731.6 in Q4 2017 to a low of -$6391.8 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ascendis Pharma A | 2.75 Bn | 2.08 Bn | 268.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -6,391.82 |
| Dec 31, 2018 | -6,391.82 |
| Dec 31, 2017 | -2,731.64 |
| Dec 31, 2017 | -2,731.64 |